Journal Article

Exome sequencing identifies molecular diagnosis in children with drug‐resistant epilepsy

Kwong, Karen Ling, Chung, Brian Hon‐Yin, Leung, Gordon Ka‐Chun, Yung, Ada Wing‐Yan, Chan, Kelvin Yuen‐Kwong, Pei, Steven Lim‐Cho, Kan, Anita Sik‐Yau, Tsang, Mandy Ho‐Yin, Mak, Christopher Chun‐Yu, Fung, Cheuk‐Wing, Ho, Alvin Chi‐Chung, Yu, Mullin Ho‐Chung, Lee, So‐Lun, Yeung, Kit‐San

2019

Overview

Summary Objective Early onset drug‐resistant epilepsy is a neurologic disorder in which 2 antiepileptic drugs fail to maintain the seizure‐free status of the patient. Heterogeneous clinical presentations make the diagnosis challenging. We aim to identify the underlying genetic causes of a pediatric cohort with drug‐resistant epilepsy and evaluate whether the findings can provide information on patient management. Methods We include patients with drug‐resistant epilepsy onset before 18 years of age. Singleton clinical chromosomal microarray (CMA) followed by whole exome sequencing (WES) was performed using genomic DNA. In the first‐tier analysis of the exome data, we aimed to identify disease‐causing mutations in 546 genes known to cause, or to be associated with, epilepsy. For negative cases, we proceeded to exome‐wide analysis. Rare coding variants were interrogated for pathogenicity based on the American College of Medical Genetics and Genomics (ACMG) guidelines. Results We recruited 50 patients. We identified 6 pathogenic or likely pathogenic mutations, giving a diagnostic yield of 12%. Mutations were found in 6 different genes: SCN8A, SCN1A, MECP2, CDKL5, DEPDC5, and CHD2. The CDKL5 variant was found to be mosaic. One variant of unknown significance (VUS) in KCNT1 was found in a patient with compatible clinical features. Of note, a reported pathogenic SCN5A mutation known to contribute to Brugada syndrome, was also found in the patient with an SCN1A mutation. Significance Our study suggests that singleton WES is an effective diagnostic tool for drug‐resistant epilepsy. Genetic diagnosis can help to consolidate the clinical diagnosis, to facilitate phenotypic expansion, and to influence treatment and management options for seizure control in our patients. In our study, a significant portion of the genetic findings are known to be associated with an increased risk of sudden unexpected death in epilepsy (SUDEP). These findings could assist with more appropriate management in patients with epilepsy.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc
• Subject: chromosomal microarray / Consortia / Data analysis / Deoxyribonucleic acid / DNA / Drug resistance / Epilepsy / Full‐length Original Research / Genes / Genetics / Genomes / Genomics / Hearing loss / Laboratories / Mutation / NMR / Nuclear magnetic resonance / Patients / Pediatrics / Pediatric‐onset drug‐resistant epilepsy / whole exome sequencing